Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces that it will present new clinical data and attend several industry conferences in February and March, all in virtual format due to the Covid-19 pandemic.
February 10, 2021
· 7 min read